Sign In
Buy CMPGY
$32.39
+0.120 (+0.372%)
At Close: Jun 03, 2026
Compass Minerals Reports Fiscal 2026 Second-Quarter Results
04:57pm, Wednesday, 06'th May 2026
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Compass Minerals (NYSE: CMP), a leading global provider of essential minerals, today reported fiscal 2026 second-quarter results. The company also announced that
Compass Diversified Reports First Quarter 2026 Financial Results
04:10pm, Wednesday, 06'th May 2026
WESTPORT, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle-market businesses, announced today its consolidated ope
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
06:30am, Wednesday, 06'th May 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:25am, Wednesday, 06'th May 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass, Inc. (COMP) Q1 2026 Earnings Call Transcript
04:01am, Wednesday, 06'th May 2026
Compass, Inc. (COMP) Q1 2026 Earnings Call Transcript
Compass, Inc. (COMP) Q1 Earnings and Revenues Top Estimates
07:05pm, Tuesday, 05'th May 2026
Compass, Inc. (COMP) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to a loss of $0.05 per share a year ago.
Compass, Inc. Reports First Quarter 2026 Results
04:05pm, Tuesday, 05'th May 2026
Actioned Over $250 Million in Net Cost Synergies in Q1 Increases 2026 Actioned Cost Synergy Target from $250 Million to $300 Million Increases 2026 Realized Cost Synergy Target from $100 Million to
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
07:30am, Tuesday, 05'th May 2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t
Compass Diversified Completes Sale of Sterno's Food Service Business
07:15am, Monday, 04'th May 2026
WESTPORT, Conn., May 04, 2026 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle-market businesses, today announced the completion, as o
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
07:42pm, Thursday, 30'th Apr 2026
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are ad
Compass, Inc. (COMP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:08am, Tuesday, 28'th Apr 2026
Compass (COMP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Behavioral and Experimental Economics Expert Ori Heffetz Affiliates With Compass Lexecon
07:30am, Tuesday, 28'th Apr 2026
WASHINGTON, April 28, 2026 (GLOBE NEWSWIRE) -- Compass Lexecon, a subsidiary of FTI Consulting, Inc. (NYSE: FCN), today announced that Dr. Ori Heffetz, a Professor of Economics at the S.C. Johnson Gra
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Compass Therapeutics, Inc. (NASDAQ: CMPX). The investigation focuses on C
Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients
11:44am, Monday, 27'th Apr 2026
Compass Therapeutics Inc. (NASDAQ:CMPX) shares are tumbling on Monday as the company announced results from its COMPANION-002 study, which evaluated its drug tovecimig in patients with advanced biliar
BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
